Literature DB >> 14870948

Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health.

Suzanne L Verheyden1, Rachel Maidment, H Valerie Curran.   

Abstract

The regular use of ecstasy (3,4-methylenedioxymethamphetamine, MDMA) has been associated with depressed mood, anxiety and hostility, but it is not known whether such effects persist after people stop using the drug. Furthermore, little is known about what factors might influence the decision to quit using MDMA. The aim of the present study was to examine the reasons why ex-users had stopped using this drug and to assess their current levels of depression, anxiety, anger and aggression. Telephone interviews were conducted with people who used to take MDMA on a regular basis but who no longer used the drug. The participants comprised sixty-six ex-users who used to take MDMA regularly (at least once every 2 months over a period of at least 1 year), but who had not taken MDMA for at least 1 year (average 3 years). Participants were asked about why they had quit MDMA. They also completed questionnaires to assess trait mood. Ex-users could be divided into two groups based on their reason for quitting: (i) those who had quit for mental health reasons and (ii) those who had quit for circumstantial reasons. Approximately half of those in the mental health group scored in the range for clinical depression. In that group, current levels of depression and anxiety correlated significantly with the cumulative amount of MDMA that they had taken several years previously. These findings suggest that some users may either be more vulnerable to the adverse effects of MDMA or have pre-existing mental health problems for which they self-medicate by using ecstasy. The present study shows that some ex-users experience an impairment to mental health that persists for years after they stop using this drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14870948     DOI: 10.1177/0269881103174014

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  13 in total

1.  MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation.

Authors:  Andrew C Parrott
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 2.  The prosocial effects of 3,4-methylenedioxymethamphetamine (MDMA): Controlled studies in humans and laboratory animals.

Authors:  Philip Kamilar-Britt; Gillinder Bedi
Journal:  Neurosci Biobehav Rev       Date:  2015-09-25       Impact factor: 8.989

3.  A longitudinal study of self-reported psychopathology in early ecstasy and amphetamine users.

Authors:  Daniel Wagner; Philip Koester; Benjamin Becker; Euphrosyne Gouzoulis-Mayfrank; Martin Hellmich; Joerg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2014-08-27       Impact factor: 4.530

4.  An examination of sociodemographic correlates of ecstasy use among high school seniors in the United States.

Authors:  Joseph J Palamar; Dimitra Kamboukos
Journal:  Subst Use Misuse       Date:  2014-06-23       Impact factor: 2.164

5.  Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study.

Authors:  Anja C Huizink; Robert F Ferdinand; Jan van der Ende; Frank C Verhulst
Journal:  BMJ       Date:  2006-02-24

6.  Psychiatric profiles of mothers who take Ecstasy/MDMA during pregnancy: reduced depression 1 year after giving birth and quitting Ecstasy.

Authors:  John J D Turner; Andrew C Parrott; Julia Goodwin; Derek G Moore; Sarah Fulton; Meeyoung O Min; Lynn T Singer
Journal:  J Psychopharmacol       Date:  2013-12-10       Impact factor: 4.153

Review 7.  A structured review of reasons for ecstasy use and related behaviours: pointers for future research.

Authors:  Gjalt-Jorn Ygram Peters; Gerjo Kok
Journal:  BMC Public Health       Date:  2009-07-13       Impact factor: 3.295

8.  Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Katherine M Keyes; Silvia S Martins; Deborah S Hasin
Journal:  Drug Alcohol Depend       Date:  2008-06-03       Impact factor: 4.492

9.  Maximising the highs and minimising the lows: harm reduction guidance within ecstasy distribution networks.

Authors:  Camille Jacinto; Micheline Duterte; Paloma Sales; Sheigla Murphy
Journal:  Int J Drug Policy       Date:  2007-10-26

10.  Depressive and anxiety symptomatology in ecstasy users: the relative contribution of genes, trauma, life stress and drug use.

Authors:  Rebecca M Scott; Leanne Hides; J Sabura Allen; Richard Burke; Dan I Lubman
Journal:  Psychopharmacology (Berl)       Date:  2010-01-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.